MiNK Therapeutics (INKT) Regains Nasdaq Compliance

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced today that it has regained compliance with the Nasdaq Capital Market’s market value of listed securities (“MVLS”) requirement.

On July 23, 2024, MiNK received notice from NASDAQ confirming that the Company has satisfied the MVLS requirement as set forth in Nasdaq Listing Rule 5550(b)(2). Accordingly, the Company now satisfies the MVLS requirement for continued listing on the NASDAQ Capital Market and the matter is now closed.

You May Also Be Interested In

• Sigma Lithium begins trading on Australian Securities Exchange
• Li Auto invests $395 million in Sunwoda battery unit
• Lululemon (LULU) PT Lowered to $100 at Stifel on Downward Revenue, EPS Revision